<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report here preliminary results of a study comparing the effect of Hemoclar and antithrombin III (AT III) in a patient with an AT III congenital deficiency </plain></SENT>
<SENT sid="1" pm="."><plain>Both drugs inhibit thrombin generation in the patient's plasma </plain></SENT>
<SENT sid="2" pm="."><plain>Unlike AT III, Hemoclar also inhibits factor Xa generation </plain></SENT>
<SENT sid="3" pm="."><plain>This led us to propose the use of Hemoclar, which acts via an AT III independent pathway, to prevent <z:mp ids='MP_0005048'>thrombosis</z:mp> in A III deficient patients </plain></SENT>
</text></document>